NCT05363670 Phase 2 Completed
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma Study sponsor: ARS Pharmaceuticals, Inc. · SPRY
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2024-02-02 Actual
Enrollment · participants 18 Actual
Source updated 2026-07-14 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-06-10 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Effect of ARS-1 versus Albuterol and placebo
+ After Measure: Effect of ARS-1 Versus Albuterol and Placebo
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial